Latest Licensing News

Meteoric Resources reports exceptional rare earth element grades and enriched magnetic rare earth oxides at its Agostinho Prospect in Brazil, signaling a potential expansion of its Caldeira Project resource base.

Evion Group has successfully raised $1.33 million through a rights issue, positioning itself to accelerate production at its Panthera JV in India. The company also announced a bonus options offer to reward shareholders and support future expansion.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Pro Medicus has inked a $53 million, seven-year contract with BayCare to deploy its Visage 7 cloud-based imaging platform across Florida’s largest healthcare system, marking a major step in its North American expansion.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.

Gold Hydrogen Limited has secured a $6.45 million R&D tax refund, strengthening its financial position ahead of an ambitious 2025 drilling campaign. The company also announced key leadership changes, including the appointment of a seasoned Chief Geologist.

Viridis Mining and Minerals has raised A$3.5 million through a placement to fund critical development milestones for its Colossus Rare Earth Element project, following a major resource upgrade.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Beamtree Holdings appoints Marek Stepniak as CEO, signaling a strategic push in international markets with a strong leadership hand familiar with the company’s growth trajectory.

Redivium Limited has successfully completed the formalities for listing a €25 million green bond, aimed at accelerating its sustainable battery recycling projects across Europe, including the UK, Czech Republic, and Romania.

Redivium Limited’s recent entitlement offer failed to meet the minimum subscription, leading to its cancellation and full refunds to investors. The company now pivots towards a green bond funding strategy to support its battery recycling ambitions.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.